Clinical trial
Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC
NCT03219762
Study timeline
Study start (actual)2017-02-07Date precision: day
Registry last updated2017-07-26
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Small Cell Lung Cancerunresolved
Interventions
NabpaclitaxelDRUG
Sponsors & collaborators
Gruppo Oncologico Italiano di Ricerca Clinicalead sponsor
Temas srlcollaborator
Clirest s.r.l.collaborator
Mipharm S.p.A.collaborator
Istituto Toscano Tumoricollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03219762 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.